(Halcinonide, USP) 0.1%
Sustained relief for busy bodies with symptoms on large body surface areas1,2
Patients suffering constant itch from eczema and atopic dermatitis need a treatment option that keeps up with their lifestyle.3
Proven results for atopic dermatitis, eczema, and psoriasis5-8
In two clinical studies, patients with psoriasis reported greater improvement after using HALOG® compared to fluocinonide cream 0.05% after 2 and 3 weeks of treatment6,7
Male with allergic contact dermatitis on his back, using HALOG® Cream twice daily for 28 days.*
*Individual patient results. Actual results may vary. Photographs courtesy of Robert C. Greenberg, MD
HALOG® CREAM can be used safely on patients of all ages8:
— with no limits on weekly dose
— on large body surface areas
Apply to the affected area 2 to 3 times daily. Rub in gently.8
Storing HALOG® Cream
HALOG® Cream should be stored at room temperature, do not place in excessive heat.8
References: 1. Draelos ZD. Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study. Cutis. 2015;96(2):135-141. 2. Baum EW. Effectiveness and patient acceptance of halcinonide 0.1% cream in 216g jars for large-area steroid-responsive dermatoses. J Clin Aesthet Dermatol. 2011;4(4):29-33. 3. Harrison IP, Spada F. Breaking the itch-scratch cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. Medicines (Basel). 2019;6(3):76. 4. Bagatell FK. Halcinonide: a new potent topical anti-inflammatory drug. Cutis. 1974;14:459-462. 5. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135–140. 6. Close JE. Double-blind comparison of topical halcinonide and fluocinonide in the treatment of psoriasis. Int J Dermatol. 1976;15(7):534-537. 7. Sudilovsky A, Clewe TH. Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eczematous dermatoses. J Clin Pharmacol. 1975;15(1112):779-784. 8. HALOG® Cream and Ointment [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2018.
INDICATIONS AND USAGE
HALOG (Halcinonide Cream, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
IMPORTANT SAFETY INFORMATION
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information of respective products.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email Drug.Safety@ranbaxy.com. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.